Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105725 | 1.00 | MAOB (0.71) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| SCHEMBL7748686 | 1.00 | MAOB (0.71) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17560820 | 0.98 | MAOB (0.69) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17560818 | 0.98 | MAOB (0.69) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| Acetic Acid SCHEMBL21519615 | 0.91 | MAOB (0.60) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| SCHEMBL19449729 | 0.86 | MAOB (0.65) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL19434712 | 0.84 | MAOB (0.63) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| SCHEMBL18131596 | 0.84 | MAOB (0.51) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| SCHEMBL18131598 | 0.84 | MAOB (0.51) | MAOBCYP1A2RAB9ANPC1ALDH1A1 | |
| SCHEMBL18133859 | 0.84 | MAOB (0.51) | MAOBCYP1A2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111896-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2018-04-26 | — | — | US | claimed |
| EP-3280405-A1 | INHIBITORS AND THEIR USES | Medical Research Council (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | claimed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | claimed |
| US-11337941-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11337941-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-24 | — | — | US | disclosed |
| US-11331286-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-17 | — | — | US | disclosed |
| US-11331286-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2022-05-17 | — | — | US | disclosed |
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | disclosed |
| EP-2991968-B1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2021-11-10 | — | — | EP | disclosed |
| US-11154519-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-10-26 | — | — | US | disclosed |
| US-11154519-B2 | Inhibitors and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-10-26 | — | — | US | disclosed |
| EP-3115357-A1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | Medical Research Council (GB) | 2017-01-11 | — | — | EP | disclosed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016162689-A1 | INHIBITORS AND THEIR USES | MEDICAL RESEARCH COUNCIL (GB) | 2016-10-13 | — | — | WO | disclosed |
| EP-2943467-B1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | MEDICAL RES COUNCIL (GB) | 2016-07-13 | — | — | EP | disclosed |
| US-20160046589-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2943467-A1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | Medical Research Council (GB) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014108520-A1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | MEDICAL RESEARCH COUNCIL (GB) | 2014-07-17 | — | — | WO | disclosed |
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111896-A1 | INHIBITORS AND THEIR USES | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885CYP1A2 4260/4885RAB9A 379/4885 |
| US-11154519-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885CYP1A2 4260/4885RAB9A 379/4885 |
| US-11331286-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885CYP1A2 4260/4885RAB9A 379/4885 |
| US-20160046589-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | MAOB 1017/4885CYP1A2 3698/4885RAB9A 88/4885 |
| US-11337941-B2 | Inhibitors and their uses | PPP1R1B, PPP5C, PPP1R15A | MAOB 3087/4885CYP1A2 4260/4885RAB9A 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.